Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation

xlomafota13 shared this article with you from Inoreader Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation Via Association française pour l'étude du cancer Bull Cancer. 2021 Feb;108(2):140-142. doi: 10.1016/j.bulcan.2020.11.010. Epub 2021 Feb 3. NO ABSTRACT PMID:33546874 | DOI:10.1016/j.bulcan.2020.11.010 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.